Golden
ImStar Therapeutics

ImStar Therapeutics

ImStar Therapeutics is company developing treatments for ALS, dementia, and other neurodegenerative diseases.

ImStar Therapeutics is a biotechnology company developing treatments for neurodegenerative diseases. The company is headquartered in Vancouver, British Columbia, Canada and was founded in 2012 by Daniel Wattier and Jean Pierre Julien.



ImStar Therapeutics is developing treatments for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), Dementia, Alzheimer's Disease, and Parkinson's Disease. The company is using its unique research findings and understanding of a protein called TAR DNA-binding protein 43 (TDP-43) and its role in inflammatory responses to develop novel treatments for neurodegenerative diseases. 

Funding

Seed Round

On June 8, 2016 ImStar Therapeutics closed their seed funding round with $1.8 million in funding from BDC Venture Capital and Accel-Rx Health Sciences Accelerator. 



Timeline

People

Name
Role
Related Golden topics

Agnes Chan

COO



Daniel Wattier

Co-Founder & CEO



David Hunt

Senior Vice President, Research and Development



Jean Pierre Julien

Co-Founder & CSO



Jeff Charpentier

CFO



Julia Levy

Board Chair



Further reading

Title
Author
Link
Type
Date

ImStar Therapeutics raises $1.8 million to research ALS treatment solutions | BetaKit

JESSICA GALANG

Web



ImStar Therapeutics Selects Lead Drug Candidate for ALS

ImStar Therapeutics

News



StemCells, Inc. Appoints Ian Massey as President and Chief Operating Officer

StemCells, Inc.

Web



Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References